Tumour heterogeneity

Tumour heterogeneity describes differences between tumours of the same type in different patients, and between cancer cells within a tumour. Both can lead to different responses to therapy. Genetic and epigenetic differences between cancer cells within a tumour might explain why some tumour cells remain present in the patient after cancer treatment has finished.

Latest Research and Reviews

News and Comment

  • News & Views |

    By quantifying thousands of proteins in tumor cells in an unbiased manner, Deep Visual Proteomics uncovers mechanisms that drive tumor evolution and reveals new therapeutic targets. The method incorporates advanced microscopy, artificial intelligence and ultra-high-sensitivity proteomics to characterize individual cell identities.

    Nature Biotechnology 40, 1186-1187
  • Research Highlights |

    In this Tools of the Trade article, Yaara Oren describes the development and use of the Watermelon system to simultaneously track the lineage, transcriptional profile and proliferative state of each cancer cell in a population, which enables the characterization of rare cycling persister cells.

    • Yaara Oren
    Nature Reviews Cancer 22, 434-435
  • News & Views |

    Prognostic models incorporating clinical and pathological parameters might assist clinicians in counselling and surveillance of patients following surgical resection of renal cell carcinoma (RCC). Variability exists in the risk classification of individual patients in each model as well as the performance of each model in different RCC subtypes.

    • Thomas Gerald
    •  & Vitaly Margulis
  • News & Views |

    A method connecting single-cell genomic, transcriptomic or proteomic profiles to functional cellular characteristics, especially time-varying phenotypic changes, would inform our understanding of cancer biology. We present functional single-cell sequencing (FUNseq) to address this need and describe how it might provide a unique way to unravel mechanisms that drive cancer.

  • News & Views |

    Tumour growth involves anomalies in cell cycle genes and emergent phenotypes, but the tumour proliferation rate (or mitotic index) is defined by just one marker, Ki-67. A study now integrates expression patterns of several markers to generate spatio-temporal maps of cell proliferation in cancer tissues.

    • Chandan Kumar-Sinha
    •  & Arul M. Chinnaiyan
    Nature Cell Biology 24, 285-287
  • Research Highlights |

    Hung, Yost, Xie et al. show that extrachromosomal DNAs (ecDNAs) are held together in hubs in the nucleus and that intermolecular interactions between ecDNAs can enhance oncogene expression.

    • Sarah Seton-Rogers